Posted by Becky Martin, NPA Advocacy Director August 6, 2014 at 7:00 PM
The NPA is an outspoken leader in the fight to reduce financial conflicts of interest in medicine. Founded with deep concern over the undue influence of the drug and device marketing in medical education, research, and clinical practice, the NPA is nearly unique among medical organizations in our refusal of funding from the pharmaceutical industry or medical device manufacturers.
In 2011 the NPA received funding through the Attorney General Consumer and Prescriber Education Grant Program to enhance the impact of our work through the Partnership to Advance Conflict-free Medical Education (PACME). This three-year initiative is working to identify and promote best practices aimed at reducing conflicts of interest with the pharmaceutical industry. As part of this project, the NPA is:
- working to expand efforts to restore integrity and trust in the medical profession through our Unbranded Doctor Network
- hosting a bimonthly Avoiding Conflict of Interest in Medicine Leadership Development Lecture Series with advocacy and policy experts to provide technical assistance and leadership development to physicians and residents
- webcasting a series of National Grand Rounds Presentations at academic medical centers to educate physicians and residents about the nature and influence of pharmaceutical industry relationships with the medical community
The Partnership to Advance Conflict‐free Medical Education (PACME)
is a joint project of the National Physicians Alliance, the American Medical Student Association, Community Catalyst, and the Pew Charitable Trusts designed to create both external and internal pressure for medical schools and academic medical centers to adopt strong new conflict-of-interest policies.
NPA is a proud partner in the Partnership to Advance Conflict‐free Medical Education (PACME). Our participation in these events is made possible by a grant from the state Attorney General Consumer and Prescriber Education Grant Program which is funded
by the multi‐state settlement of consumer fraud claims regarding the marketing
of the prescription drug Neurontin.